Dataset Information

Whole transcriptome expression profiling of pancreatic cancers patients with T4 stage but diametrically opposing survival outcomes

ABSTRACT: Pancreatic cancer is a highly malignant tumor in the digestive tract, with its incidence increasing year by year. Due to the insidious onset and rapid progression, most patients have already advanced disease at the time of the initial diagnosis, and the overall 5-year survival rate was only 11%. Tumors in T4 stage often have the invasion of key upperabdominal vessels, mainly referring to artery-involved pancreatic cancer with a worse prognosis. Resection of pancreatic ductal adenocarcinoma (PDAC) with T4 stage is more challenging and usually needs advanced surgical techniques including treatment of the involved artery including sub-adventitial divestment technique (SDT) and arterial resection with reconstruction, and periarterial dissection such as the Heidelberg Triangle Operation. SDT means a technique to separate the tumor from the artery by dissecting into the plane between the external elastic lamina (EEL) and the tunic media when the tumor was not invaded to EEL of the involved artery. Our previous study revealed that SDT procedure appears to be relatively safe, without excessive mortality, as compared to arterial resection with reconstruction. However, survival times can vary widely among different patients. So a strategy to select the T4 patients who may benefit from the surgery with SDT procedure is urgently needed. Our previous RNA-seq dataset has identified a series of differentially expressed circRNAs including circNEIL3 and circRHOBTB3 in PDACs. These results suggested that circRNAs might be prominent prognostic markers for PDAC. So to explore the prognostic value of circRNAs in pancreatic cancer and seek a useful biomarker for distinguishing specified population with a good prognosis from the whole T4 patients, we further performed whole transcriptome sequencing including miRNAs, mRNAs, lncRNAs and circRNAs in ten PDAC cancer samples with T4 stage but diametrically opposing survival outcomes. They all underwent radical surgery and received the assessments of pre- and post-operative contrast-enhanced computed tomography, five of these patients developed newly discovered metastasis soon after surgery and died within 4-9 months. In contrast, the other five patients had no recurrence or metastasis and had long-term survival for more than 39 months. We systematically identified differentially expressed circRNAs in our previous dataset and in patients with T4 stage through combining three popular circRNAs detection algorithms (CIRI2 v2.0.6, CIRCexplorer2 v2.3.8, and find_circ v1.2) and two differential analysis methods (DEGseq and DEseq). Results were validated by using quantitative RT-PCR. circRNA alternative splicing events and highly expressed circRNAs with high circular ratio were also identified by CircSplice and CIRCexplorer3-CLEAR pipeline.

ORGANISM(S): Homo sapiens

PROVIDER: GSE201358 | GEO | 2022/04/25

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma Pancreatic ductal adenocarcinoma (PDAC), comprising over 90% of all pancreatic cancers, remains a lethal disease with an estimated 232,000 new cases, 227,000 deaths per year worldwide, and a less than 5% five-year survival rate. Currently the standard of care for the 20% of patients with localized disease is surgery followed by chemotherapy, and in some cases radiation. Unfortunately despite the use of adjuvant therapy, median survival remains at best 23 months. It is important to note however, that up to 27% of patients with resected PDAC can survive for five years. However, in these studies examining actual long-term survivors, only two have found that adjuvant therapy was associated with improved survival. In addition, randomized controlled trials of gemcitabine-based chemotherapy demonstrate an improvement in median survival of at best 3 months. One possible conclusion from these studies is that tumor biology dictates outcome and that our current adjuvant therapy has only a modest impact on altering a patient's course.Hypothesizing that the dismal outcome of patients with localized disease is due to the presence of micrometastasic disease, current clinical investigation has focused on preoperative or neoadjuvant therapy. This approach, where patients who cannot tolerate the stress of therapy or develop metastatic disease during treatment are spared surgery, has demonstrated an overall survival of 34 months in this highly selected patient population. Therefore the ability to select patients who would most benefit from a neoadjuvant approach may be important. One way to do this is to define a prognostic gene signature that can identify patients with more aggressive tumor biology upfront. reference x sample The 30 Nebraska and UNC samples were not analyzed with clinical data so it is not provided. One of the PE samples is missing some clinical data.

Project description:Most cancer deaths are caused by metastases, which are the end-results of circulating tumor cells (CTC) that detach from the cancer primary and succeed to survive in distant organs. The aim of the present study was to develop a gene signature of CTC and to assess its prognostic relevance after surgery for pancreatic ductaladenocarcinoma (PDAC). A negative depletion fluorescence activated cell sorting (FACS) procedure was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumor (T), and non-tumoral pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. The ‘Ingenuity Pathway Analysis’ software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS). Using stringent statistical analysis, we finally retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were over-expressed in CTC. High co-expression of TGF-1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 4 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 – 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 – 1.861)). Pancreatic CTC isolated from blood samples using a FACS-based negative depletion method,express a cell motility gene signature. The expression of this newly defined cell motility gene signature in the primary tumor is able to predict survival of patients who undergo surgical resection for pancreatic cancer. Total RNA was isolated from circulation tumor samples (CTC), haematological cells (G), original tumor (T), and non-tumor pancreatic control tissue (P) of patients with pancreatic ductal adenocarcinoma (PDAC). Gene expression profiles of CTC were compared to G, T, and P. The aim of the current study was to develop a ‘negative depletion strategy’ to isolate CTC without the exclusion of any particular subset of CTC, and to study their gene-expression profiles in order to find novel therapeutic targets and prognostic markers in patients with pancreatic cancer.

Dataset Information

Whole transcriptome expression profiling of pancreatic cancers patients with T4 stage but diametrically opposing survival outcomes

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets